Dapagliflozin affects hepatic steatosis in NAFLD by downregulating lipogenic enzymes and activating the AMPK-mTOR pathway, while promoting fatty acid oxidation and autophagy to mitigate disease progression. This evidence concerns the gene MTOR and Hepatic steatosis.